Business context and reporting period
Chewy, Inc. operates an online pet-products and healthcare business through its website and mobile applications, including its Autoship subscription program. The supplied filing is a Form 10-Q for the 13 weeks ended October 31, 2021, with year-to-date results for the 39 weeks ended October 31, 2021. This conflicts with the request metadata identifying 2020 Q3; the filing itself reports 2021 Q3.
Key financial metrics
| Metric | 13 weeks ended Oct. 31, 2021 | Prior-year comparable | 39 weeks ended Oct. 31, 2021 | Prior-year comparable |
|---|---|---|---|---|
| Net sales | $2.212 billion | $1.782 billion | $6.502 billion | $5.103 billion |
| Gross profit / margin | $584.8 million / 26.4% | $454.6 million / 25.5% | $1.768 billion / 27.2% | $1.267 billion / 24.8% |
| Operating loss | $(31.9) million | $(32.3) million | $(9.0) million | $(112.1) million |
| Net loss | $(32.2) million | $(32.8) million | $(10.2) million | $(113.5) million |
| Adjusted EBITDA (non-GAAP) | $6.0 million | $5.5 million | $106.7 million | $24.4 million |
| Operating cash flow | $74.3 million | $63.4 million | $257.7 million | $55.3 million |
| Free cash flow (non-GAAP) | $2.3 million | $32.9 million | $122.0 million | $(45.0) million |
At October 31, 2021, cash and cash equivalents were $726.9 million; current assets were $1.524 billion and current liabilities were $1.719 billion. The company had no ABL borrowings and reported $463.3 million of borrowing capacity. Operating lease liabilities totaled $401.1 million, including current amounts. The filing reports no income-tax provision for the periods and a full valuation allowance on net deferred tax assets.
Material changes versus prior comparable periods
- Quarterly sales rose 24.1%; year-to-date sales rose 27.4%. Management attributed growth to a 14.7% increase in active customers to 20.4 million and a 15.4% increase in net sales per active customer to $419.
- Autoship customer sales increased 26.7% in the quarter and represented 70.6% of sales, versus 69.2% a year earlier.
- Gross margin expanded 90 basis points for the quarter and 240 basis points year to date. Management cited margin expansion across consumables, hardgoods, and healthcare, with faster growth in healthcare and proprietary brands.
- Quarterly operating expenses rose 26.7%, faster than sales, with SG&A up 32.4%. Management cited fulfillment-center and customer-service expansion, higher wages and recruiting costs, increased headcount, new offices, and IT investment.
- Year-to-date operating cash flow increased substantially, supported in part by working-capital movements, including higher payables. Capital expenditures were $135.7 million year to date, up from $100.3 million; quarterly free cash flow fell to $2.3 million from $32.9 million.
Outlook, risks, contingencies, and unusual items
- The filing provides no specific financial guidance. Management said cash and cash equivalents plus revolver availability should be sufficient for working capital, capital expenditures, and contractual obligations for at least 12 months.
- Management described fulfillment labor markets as challenging, with competition for personnel and higher wage and recruiting costs expected to persist in the near to medium term. COVID-19’s ultimate impact remains difficult to predict; online channel shifts had supported sales, while supply chain, workforce, and operating risks remain.
- The ABL facility was amended in August 2021: commitments increased to $500 million, incremental facility capacity to $300 million, and maturity extended to August 2026.
- IBM alleges infringement of patents relating to Chewy’s website and app and seeks unspecified damages, potentially trebled, injunctive relief, and costs. One of five asserted patents was eliminated following claim-construction rulings; discovery is continuing. Chewy denies infringement, and the potential loss or range of loss is not estimable.
- Year-to-date share-based compensation expense was $63.7 million, versus $100.2 million a year earlier. Tax-sharing agreement receipts were $43.7 million year to date; a $1.3 million receivable was expected to be collected during fiscal 2021.
- Management reported disclosure controls were effective at a reasonable-assurance level and no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended reporting period: the source is 2021 Q3, not 2020 Q3 as stated in the request metadata.
- Assess whether sales and active-customer growth can continue as pandemic-related shopping patterns normalize.
- Track gross-margin gains against fulfillment, labor, advertising, and infrastructure costs, and distinguish GAAP results from non-GAAP adjusted EBITDA and free cash flow.
- Review cash conversion and working-capital trends, particularly the contribution from payables, inventory, and capital spending.
- Monitor the IBM litigation and other disclosed contingencies; the filing gives no estimable loss range for the IBM matter.